Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2025 slightly exceeded previous expectations, with total revenue of HKD 14.58 billion, a year-on-year increase of 11.5%, and a net profit attributable to shareholders of HKD 980.29 million, up 14.82% year-on-year [7] - The company is expected to continue improving its profit margins, with a projected gross margin of 10.43% in 2026, up from 10.1% in 2025 [7] - The company is positioned as the only publicly listed entity under China Tobacco International, focusing on the export of tobacco products and expanding its global footprint [7] Financial Projections - Total revenue projections for the company are as follows: - 2024: HKD 13.07 billion - 2025: HKD 14.58 billion - 2026: HKD 15.77 billion - 2027: HKD 17.16 billion - 2028: HKD 18.54 billion - The net profit attributable to shareholders is projected to be: - 2024: HKD 853.74 million - 2025: HKD 980.29 million - 2026: HKD 1.10 billion - 2027: HKD 1.34 billion - 2028: HKD 1.56 billion [1][8] - The earnings per share (EPS) forecast is as follows: - 2024: HKD 1.23 - 2025: HKD 1.42 - 2026: HKD 1.59 - 2027: HKD 1.94 - 2028: HKD 2.26 [1][8] Business Segmentation - Revenue from different business segments in 2025 includes: - Tobacco leaf imports: HKD 9.54 billion (up 16% year-on-year) - Tobacco leaf exports: HKD 2.48 billion (up 20% year-on-year) - Cigarette exports: HKD 1.67 billion (up 6% year-on-year) - New tobacco products: HKD 0.06 billion (down 52% year-on-year) - Brazilian operations: HKD 0.83 billion (down 21% year-on-year) [7] - The company plans to optimize its supply chain, which is expected to enhance the gross margin of its cigarette export business [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2025 slightly exceeded previous expectations, with total revenue reaching HKD 14.58 billion, a year-on-year increase of 11.5%. The gross profit was HKD 1.47 billion, up 7% year-on-year, and the net profit attributable to shareholders was HKD 980.29 million, reflecting a year-on-year growth of 15% [7] - The company is expected to continue improving its profit margins, with a projected gross margin of 10.1% for 2025, slightly down by 0.4 percentage points year-on-year. The gross margins for various business segments are expected to improve due to better pricing strategies and increased scale [7] - The company is positioned as the only publicly listed entity under China Tobacco International, focusing on the export of tobacco products and expanding its global footprint, which is anticipated to drive further growth [7] Financial Summary - Total revenue projections for the company are as follows: HKD 13.07 billion in 2024, HKD 14.58 billion in 2025, HKD 15.77 billion in 2026, HKD 17.16 billion in 2027, and HKD 18.54 billion in 2028, with respective year-on-year growth rates of 10.46%, 11.51%, 8.19%, 8.77%, and 8.07% [1] - The net profit attributable to shareholders is projected to be HKD 853.74 million in 2024, HKD 980.29 million in 2025, HKD 1.10 billion in 2026, HKD 1.34 billion in 2027, and HKD 1.56 billion in 2028, with year-on-year growth rates of 42.58%, 14.82%, 12.08%, 22.38%, and 16.33% respectively [1] - The earnings per share (EPS) are expected to be HKD 1.23 in 2024, HKD 1.42 in 2025, HKD 1.59 in 2026, HKD 1.94 in 2027, and HKD 2.26 in 2028, with a corresponding price-to-earnings (P/E) ratio decreasing from 30.71 in 2024 to 16.76 in 2028 [1]

Investment Rating - The investment rating for China Tobacco Hong Kong (6055.HK) is upgraded to "Buy" [1]. Core Insights - The company demonstrated robust performance in 2025, with revenue and profit both showing double-digit growth. The dividend payout ratio remains stable. The company actively integrates resources across categories and markets, achieving progress in tobacco leaves, cigarettes, and Brazilian operations, contributing to sustained growth [2]. Financial Summary - Total revenue for 2025 is projected at HKD 14,579 million, reflecting a year-on-year increase of 11.5% - Net profit is expected to reach HKD 980 million, up 14.8% year-on-year - Gross profit margin stands at 10.1%, a decrease of 0.4 percentage points - For the second half of 2025, revenue is estimated at HKD 4,260 million, down 2.5%, while net profit is projected at HKD 270 million, an increase of 30.2% - The company plans to pay dividends of HKD 0.32, HKD 0.46, and HKD 0.52 per share for 2023-2025, maintaining a dividend payout ratio of around 37% [4][10]. Revenue Breakdown - Revenue from imported tobacco leaves is expected to be HKD 9,540 million, up 15.6% year-on-year (volume down 1.0%, price up 16.8%) - Revenue from exported tobacco leaves is projected at HKD 2,480 million, an increase of 20.4% year-on-year (volume up 3.1%, price up 16.8%) - Revenue from cigarette exports is estimated at HKD 1,670 million, up 5.9% year-on-year (volume down 3.3%, price up 9.6%) - Revenue from new tobacco products is expected to decline to HKD 60 million, down 52.4% year-on-year (volume down 51.2%, price down 2.6%) - Revenue from Brazilian operations is projected at HKD 830 million, down 21.0% year-on-year (volume down 4.2%, price down 17.6%) [10]. Future Projections - The company has raised its EPS forecasts for 2026 and 2027 to HKD 1.64 and HKD 1.95, respectively, with a target price of HKD 44 based on a 27x PE for 2026. The expected EPS for 2028 is HKD 2.21 [10][12].

Core Viewpoint - Cathay Securities maintains a "Buy" rating for China Tobacco Hong Kong (06055) and raises the EPS forecast for 2026-2027 to HKD 1.64/1.95 from HKD 1.58/1.75, with a target price of HKD 44 based on a 27X PE for 2026, considering the company's growth potential and expansion logic [1] Group 1: Financial Performance - The company expects a stable performance in 2025, with projected revenue of HKD 14.58 billion, a year-on-year increase of 11.5%, and a net profit of HKD 980 million, up 14.8%, with a gross margin of 10.1%, down 0.4 percentage points [1] - For the second half of 2025, revenue is anticipated to be HKD 4.26 billion, down 2.5%, while net profit is expected to rise by 30.2% to HKD 270 million, suggesting a need to view the full year performance collectively [1] - Shareholder returns are projected with dividends of HKD 0.32/0.46/0.52 per share for 2023-2025, maintaining a payout ratio of around 37% [1] Group 2: Revenue Breakdown - For 2025, the revenue from imported tobacco leaf products is expected to be HKD 9.54 billion, a year-on-year increase of 15.6%, with a decrease in gross margin by 1.9 percentage points due to increased costs from Brazilian tobacco leaf procurement [2] - Revenue from exported tobacco leaf products is projected at HKD 2.48 billion, up 20.4%, with a gross margin increase of 2.2 percentage points, benefiting from price increases [2] - Revenue from cigarette exports is expected to reach HKD 1.67 billion, a 5.9% increase, with a gross margin improvement of 5.2 percentage points to 22.8%, driven by a higher proportion of duty-free self-operated sales [2] - New tobacco product exports are projected to decline significantly by 52.4% to HKD 60 million, primarily due to international events [2] - The Brazilian operations are expected to generate HKD 830 million, down 21.0%, influenced by both volume and price declines [2] Group 3: Strategic Initiatives - The company is actively expanding its business by integrating resources and exploring new markets, with changes in tobacco leaf and cigarette export operations expected in 2026 [3] - The company has initiated tobacco leaf procurement from China Tobacco North America and sales to third parties, with expected transaction limits significantly higher than in 2025 [3] - As the only state-owned enterprise with the qualification to export cigarettes to the domestic duty-free market, China Tobacco Hong Kong is expected to enhance its revenue and profitability through collaboration with China Tobacco International [3]

Core Viewpoint - Cathay Securities maintains a "Buy" rating for China Tobacco Hong Kong (06055) and raises the EPS forecast for 2026-2027 to HKD 1.64/1.95 from HKD 1.58/1.75, with a target price of HKD 44 based on a 27X PE for 2026, considering the company's growth potential and expansion logic [1] Group 1: Financial Performance - The company expects a stable performance in 2025, with projected revenue of HKD 14.58 billion, a year-on-year increase of 11.5%, and a net profit of HKD 980 million, up 14.8%, with a gross margin of 10.1%, down 0.4 percentage points [1] - For the second half of 2025, revenue is anticipated to be HKD 4.26 billion, down 2.5%, while net profit is expected to rise by 30.2% to HKD 270 million, suggesting a need to view the full year performance collectively [1] - The company plans to distribute dividends of HKD 0.32/0.46/0.52 per share from 2023 to 2025, maintaining a payout ratio of around 37% [1] Group 2: Revenue Breakdown - For 2025, the revenue from imported tobacco leaf products is projected at HKD 9.54 billion, a year-on-year increase of 15.6%, with a decrease in gross margin by 1.9 percentage points due to rising costs from Brazilian tobacco leaf procurement [2] - Revenue from exported tobacco leaf products is expected to reach HKD 2.48 billion, up 20.4%, with a gross margin increase of 2.2 percentage points, benefiting from price increases [2] - Revenue from cigarette exports is projected at HKD 1.67 billion, a 5.9% increase, with a gross margin improvement of 5.2 percentage points to 22.8%, driven by a higher proportion of duty-free self-operated sales [2] - New tobacco product exports are expected to decline significantly by 52.4% to HKD 60 million, primarily due to international events [2] - Revenue from Brazilian operations is projected to decline by 21.0% to HKD 830 million, influenced by changes in product structure [2] Group 3: Business Expansion - The company is actively expanding its business by integrating resources and exploring new markets, with changes in tobacco leaf and cigarette export operations expected in 2026 [3] - The company has initiated tobacco leaf procurement from China Tobacco North America and sales to third parties, with expected transaction limits significantly higher than in 2025 [3] - As the only state-owned enterprise with the qualification to export cigarettes to the domestic duty-free market, China Tobacco Hong Kong is expected to enhance its revenue and profitability through collaboration with China Tobacco International [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a solid revenue growth of HKD 14.58 billion for the fiscal year ending December 31, 2025, representing a year-on-year increase of 11.5%. The net profit attributable to shareholders reached HKD 0.98 billion, up 14.8% year-on-year. The revenue growth was primarily driven by the export of leaf products and cigarettes, while profit growth was supported by the same export businesses and a decrease in financing costs [4] - The board proposed a final dividend of HKD 0.33 per share, in addition to an interim dividend of HKD 0.19 per share, bringing the total annual dividend to HKD 0.52 per share, which is a 13.0% increase year-on-year [4] Business Segment Performance - The revenue from the leaf product import business was HKD 95.38 billion, a 15.6% increase year-on-year, despite a 1.0% decrease in import volume to 110,800 tons. The gross profit was HKD 0.772 billion, down 6.5% year-on-year [5] - The leaf product export business saw a revenue of HKD 24.81 billion, up 20.4% year-on-year, with an export volume of 86,100 tons, a 3.1% increase. The gross profit surged by 86.8% to HKD 0.157 billion, attributed to enhanced customized services and improved pricing strategies [5] - The cigarette export business generated HKD 16.66 billion in revenue, a 5.9% increase year-on-year, with an export volume of 3.228 billion sticks, down 3.3%. The gross profit rose by 37.2% to HKD 0.381 billion, driven by the expansion of self-operated channels [5] - The new tobacco product export business faced a significant decline, with revenue dropping to HKD 0.64 billion, down 52.5% year-on-year, and an export volume decrease of 51.2% [5] - The Brazilian operations reported a revenue of HKD 8.29 billion, down 21.0% year-on-year, with a decrease in export volume to 30,300 tons, down 4.2% [5] Strategic Outlook - The company aims to leverage both organic growth and external expansion to seize new development opportunities, focusing on international market expansion and investment platform positioning. It plans to enhance supply chain collaboration and diversify its product offerings [6] - The company is committed to increasing its market presence in the cigar segment and addressing geopolitical challenges affecting the international supply chain [7] Financial Projections - The company is expected to achieve total revenues of HKD 15.18 billion, HKD 16.28 billion, and HKD 17.44 billion for the years 2026, 2027, and 2028, respectively, with year-on-year growth rates of 4%, 7%, and 7% [8] - The net profit attributable to shareholders is projected to be HKD 1.08 billion, HKD 1.21 billion, and HKD 1.37 billion for the same years, reflecting growth rates of 10%, 12%, and 13% [8] - The earnings per share (EPS) is forecasted to be HKD 1.56, HKD 1.75, and HKD 1.98 for 2026, 2027, and 2028, respectively, with corresponding price-to-earnings (P/E) ratios of 24.74, 22.03, and 19.48 [8]

Investment Rating - The investment rating for China Tobacco Hong Kong (06055.HK) is "Buy" (maintained) [1] Core Views - The report highlights that China Tobacco Hong Kong is the only company authorized to export cigarettes to the domestic duty-free market, which is expected to enhance its gross profit margin [7] - The implementation of new regulations on January 1, 2026, will optimize the supply chain for cigarette exports, leading to improved profitability [7] - The company is projected to see steady growth in revenue and net profit, with significant increases expected in the coming years [1][7] Financial Projections - Total revenue is forecasted to grow from HKD 11,836 million in 2023 to HKD 17,470 million by 2027, reflecting a compound annual growth rate (CAGR) of approximately 8.71% [1] - Net profit attributable to shareholders is expected to rise from HKD 598.77 million in 2023 to HKD 1,300.22 million in 2027, with a notable increase of 59.71% in 2023 [1] - The earnings per share (EPS) is projected to increase from HKD 0.87 in 2023 to HKD 1.88 in 2027, indicating a strong upward trend [1] Profitability Metrics - The gross profit margin for the cigarette export business is anticipated to improve, with a reported margin of 17.6% in 2024 and an expected increase to 25.7% in the first half of 2025 [7] - The report estimates that the company will achieve a price-to-earnings (P/E) ratio of 34, 30, and 24 for the years 2025, 2026, and 2027 respectively, reflecting a positive outlook on valuation [1][7] Market Position - China Tobacco Hong Kong serves as the only publicly listed platform for China Tobacco's international business, with a robust development in the import and export of tobacco leaf products [7] - The company is positioned to leverage its unique status and regulatory advantages to enhance its market share and profitability in the duty-free segment [7]

Core Viewpoint - China Tobacco Hong Kong (06055) has signed significant tobacco sales framework agreements, indicating strong future business growth confidence and potential expansion into new markets [1] Group 1: Stock Performance - China Tobacco Hong Kong's stock rose over 4%, specifically 4.23%, reaching HKD 42.36, with a trading volume of HKD 47.4351 million [1] Group 2: Agreements and Financial Projections - The company signed a framework agreement with Leaf Trading, setting annual transaction limits for 2026, 2027, and 2028 at HKD 6.7 million, HKD 8.4 million, and HKD 9.8 million respectively [1] - A framework agreement with China Tobacco International (North America) was established for the export of tobacco leaf products to new regions, with increased annual transaction limits for 2026 and 2027 set at HKD 466 million and HKD 490 million, reflecting increases of 538.4% and 456.8% respectively [1] Group 3: Strategic Implications - The significant adjustment in transaction limits demonstrates the company's confidence in future business growth [1] - The procurement agreements are expected to enhance the export of tobacco leaf products to Southeast Asia, diversify customer structures, and attract more potential buyers from broader regions [1] - The company aims to secure high-quality raw material supplies, gradually expanding beyond exclusive sales regions, thereby increasing its growth potential [1]

Core Viewpoint - The company has entered into a framework agreement with Leaf Trading for the sale of tobacco leaf products, which is expected to enhance its business development and meet global market demand for these products [1] Group 1: Agreement Details - The agreement with Leaf Trading is set to commence on January 27, 2026, focusing on the sale of tobacco leaf products [1] - The company anticipates that other contacts globally, such as Pyxus, will also procure tobacco leaf products for their production needs or for resale to end customers [1] Group 2: Business Development - The framework agreement is seen as a significant step towards further business development for the company [1] - The company aims to generate additional revenue by satisfying overseas demand for tobacco leaf products, aligning with its business and commercial objectives [1]

Core Viewpoint - The company has entered into a framework agreement with Leaf Trading for the sale of tobacco leaf products, which is expected to enhance its business development and meet global market demand for these products [1] Group 1: Agreement Details - The agreement with Leaf Trading is set to commence on January 27, 2026, focusing on the sale of tobacco leaf products [1] - The company anticipates that other contacts globally, such as Pyxus, will also procure tobacco leaf products for their production needs or for resale to end customers [1] Group 2: Business Development - The framework agreement is seen as a significant step towards further business development for the company [1] - The company aims to generate additional revenue by satisfying overseas demand for tobacco leaf products, aligning with its business and commercial objectives [1]